Arizona State Retirement System Grows Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Arizona State Retirement System grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,890 shares of the biotechnology company’s stock after purchasing an additional 394 shares during the period. Arizona State Retirement System’s holdings in Sarepta Therapeutics were worth $3,026,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Proficio Capital Partners LLC purchased a new stake in Sarepta Therapeutics during the 4th quarter worth $3,829,000. Assetmark Inc. grew its stake in shares of Sarepta Therapeutics by 9.6% during the fourth quarter. Assetmark Inc. now owns 42,759 shares of the biotechnology company’s stock valued at $5,199,000 after acquiring an additional 3,734 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of Sarepta Therapeutics by 34.0% during the fourth quarter. Victory Capital Management Inc. now owns 88,808 shares of the biotechnology company’s stock worth $10,798,000 after acquiring an additional 22,529 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Sarepta Therapeutics by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company’s stock worth $75,842,000 after acquiring an additional 12,000 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its stake in shares of Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 194 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 7.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

SRPT has been the subject of a number of recent analyst reports. Royal Bank of Canada lowered their price objective on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. Scotiabank initiated coverage on shares of Sarepta Therapeutics in a research report on Friday. They set a “sector perform” rating and a $105.00 price target for the company. Deutsche Bank Aktiengesellschaft began coverage on shares of Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price target on the stock. HC Wainwright reissued a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $170.41.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $103.03 on Monday. Sarepta Therapeutics, Inc. has a 1 year low of $99.50 and a 1 year high of $173.25. The stock has a market capitalization of $10.00 billion, a price-to-earnings ratio of 82.42 and a beta of 0.79. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The stock’s fifty day moving average is $114.11 and its two-hundred day moving average is $121.27.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.